Orphenadrine hydrochloride - CAS 341-69-5
Catalog: |
BB021989 |
Product Name: |
Orphenadrine hydrochloride |
CAS: |
341-69-5 |
Synonyms: |
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;hydrochloride |
Application: |
Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. |
Related CAS: | 4682-36-4 (Citrate)
|
IUPAC Name: | N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;hydrochloride |
Description: | A skeletal muscle relaxant used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. |
Molecular Weight: | 305.84 |
Molecular Formula: | C18H23NO · HCl |
Canonical SMILES: | CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.Cl |
InChI: | InChI=1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H |
InChI Key: | UQZKYYIKWZOKKD-UHFFFAOYSA-N |
Boiling Point: | 363 ℃ at 760 mmHg |
Melting Point: | 313 to 315 °F |
Purity: | > 98 % |
Density: | 1.014 g/cm3 |
Solubility: | Soluble in DMSO |
Appearance: | White solid |
Storage: | Store at RT. |
LogP: | 4.46460 |
Quality Standard: | Enterprise Standard/EP |
GHS Hazard Statement: | H301 (97.62%): Toxic if swallowed [Danger Acute toxicity, oral] |
Precautionary Statement: | P264, P270, P301+P316, P321, P330, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
WO-2021005189-A1 | Novel pfar-inhibiting compounds | 20190709 |
US-2020163616-A1 | Devices, systems, and methods to monitor subject compliance with a pharmaceutical treatment regimen | 20181128 |
WO-2020112814-A1 | Devices, systems, and methods to monitor subject compliance with a pharmaceutical treatment regimen | 20181128 |
US-2020138730-A1 | Lipophilic active oral film formulation and method of making the same | 20181105 |
US-2020131431-A1 | Chemical additives and surfactant combinations for favorable wettability alteration and improved hydrocarbon recovery factors | 20181026 |
PMID | Publication Date | Title | Journal |
23665939 | 20130101 | Liver tumor promoting effect of orphenadrine in rats and its possible mechanism of action including CAR activation and oxidative stress | The Journal of toxicological sciences |
23665940 | 20130101 | Enhanced liver tumor promotion activity in rats subjected to combined administration of phenobarbital and orphenadrine | The Journal of toxicological sciences |
22573364 | 20120611 | Cu(II)-catalyzed asymmetric hydrosilylation of diaryl- and aryl heteroaryl ketones: application in the enantioselective synthesis of orphenadrine and neobenodine | Chemistry (Weinheim an der Bergstrasse, Germany) |
22419134 | 20120314 | [Interaction of drugs with the primary disease - when medicines exacerbate illnesses] | Praxis |
22302057 | 20120101 | Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: an open-label pilot study | Audiology & neuro-otology |
Complexity: | 260 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 2 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 305.1546421 |
Formal Charge: | 0 |
Heavy Atom Count: | 21 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 305.1546421 |
Rotatable Bond Count: | 6 |
Topological Polar Surface Area: | 12.5 |
Undefined Atom Stereocenter Count: | 1 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Nitrogen Compounds
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS